Status:
COMPLETED
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborating Sponsors:
Hyphen BioMed
CIC-EC de Saint-Etienne
Conditions:
Heparin-induced Thrombocytopenia
Eligibility:
All Genders
18+ years
Brief Summary
Although Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatment, it results in a high rate of morbidity and mortality, the cumulative rate of thrombosis recurrence, amputat...
Detailed Description
Purpose : To create and validate a score predicting the diagnosis of HIT
Eligibility Criteria
Inclusion
- all patients presenting, either during or immediately after treatment:
- thrombocytopenia and/or venous or arterial thrombosis
- for whom a request for biological assessment to check for HIT (anti-H-PF4 ELISA test) is to be addressed to the specialized haemostasis laboratory participating in the study
Exclusion
- do not possess sufficient clinical data prior to performance of the biological test
- cannot assure follow-up of the patient until normalization of the platelet count
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
2700 Patients enrolled
Trial Details
Trial ID
NCT00748839
Start Date
March 1 2009
End Date
November 1 2012
Last Update
November 27 2012
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
ETS de Franche Conté - Laboratoire d'Immuno Hématologie
Besançon, France, 25020
2
CHU Cavale Blanche Laboratoire d'Hématologie
Brest, France, 29609
3
Laboratoire d'hématologie - Hôpital Louis Pradel
Bron, France, 69500
4
Hôpital Antoine Beclère - Laboratoire d'hématologie
Clamart, France, 92141